Title : De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.

Pub. Date : 2022 May

PMID : 34651261






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: The current guidelines recommend potent P2Y12 prasugrel or ticagrelor for 12 months despite their association with a high risk of bleeding. Prasugrel Hydrochloride purinergic receptor P2Y12 Homo sapiens